Zydus Cadila gets USFDA nod for 800 mg Mesalamine delayed-re
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Zydus Cadila has received final approval from USFDA for generic Mesalamine delayed-release tablets, in the strength of 800 mg, used for the treatment of mildly to moderately active ulcerative colitis and for the maintenance of remission of ulcerative colitis...
Preview
Like
Comment
Share